This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Dr. Aileen Marty, Infectious Disease ...
They aren't just "pandemic stocks." ...
Hosted on MSN
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). These two vaccine makers ...
The packing and shipping of a third COVID-19 vaccine approved for use in the U.S. is underway. Johnson & Johnson’s single-dose shot will start going into Americans’ arms in a matter of days. Nearly 4 ...
Moderna COVID-19 vaccines were associated with a threefold increased risk of chronic urticaria and nearly fourfold increased risk of other types of urticaria compared to expected rates.
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech traded blows this week with rival Moderna as dueling decisions came down in the ...
Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD treatment was rejected by an FDA advisory committee. Pfizer's PD-1xVEGF deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results